Overview
The clinical study is a randomized (1:1:1), double-blind, placebo-controlled clinical study. Recruit patients with moderate to severe depression. After signing the informed consent, patients who meet the inclusion criteria will be randomly assigned to the ATP group (fluoxetine combined with ATP) or phosphocreatine group (fluoxetine combined with phosphocreatine) or control group (fluoxetine combined with 0.9% sodium chloride) to received treatment. Then accessed scale, cognitive function and brain function before treatment and at one, two, and four weeks after treatment to initially explore the safety and efficacy of ATP combined with fluoxetine to rapidly improves moderate to severe depression.
Eligibility
Inclusion Criteria:
- Meet DSM-V diagnostic criteria for moderate to severe depression.
- HAMD-24 scores ≥ 20.
- 18-65 female or male.
- Subjects who have not used any antipsychotic drugs, antidepressants, mood stabilizers (sodium valproate, lithium carbonate) or fluoxetine treatment within the first month prior to the start of this study
- Written informed consent.
Exclusion Criteria:
- Sufferring from various major mental disorders other than depression (such as bipolar disorder, schizophrenia, personality split, etc.).
- Individuals with neurological disorders such as dementia.
- Individuals with a high risk of suicide.
- Pregnant and lactating women.
- Individuals with alcohol or drug abuse or dependence within one year prior to the start of this study.
- Contraindications to MRI.
- Physician evaluation was not suitable for participants in this study.